Photos from Envato
The rise is partly attributed to the increased survival rate caused by modern medicine.
GlobalData said that in eight major markets (8mm), the five-year burden of predicted five-year diagnosis of prostate cancer cases is expected to increase by 3.10% to 4.24 million per year.
The rise is partly attributed to increased patient survival due to potential demographic changes in modern medicine and various markets.
Meanwhile, prostate-specific antigen (PSA) testing is expected to affect the epidemiology of cancer cases, said Bishal Bhandari, associate director of epidemiology at GlobalData.
“PSA screening can detect prostate cancer early, but it can also lead to the discovery of non-living tumors, leading to unnecessary anxiety,” Bhandari added.
8mm = United States, France, Germany, Italy, Spain, United Kingdom, Japan and China
Join the Healthcare Asia Magazine Community
Since you're here…
…You can promote your company with us and connect with your customers in a variety of ways. Our team can help you Dight and create advertising campaigns on print and digitally on this website and on print magazines.
We can also organize real-life or digital events for you and find thought leader speakers and industry leaders who can become your potential partners to attend. We also run a number of award programs that give you the opportunity to earn your achievements this year and you can join as a participant or sponsor.
Let us help you move your business forward with a good partnership!
